Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Helix BioPharma ( (TSE:HBP) ) has provided an update.
Helix BioPharma has extended metaShape Pharma’s exclusive research and option agreement for LEUMUNA in adipose tissue-related and metabolic diseases through December 31, 2028, preserving Helix’s rights to a potential high-value metabolic program while keeping its core strategic emphasis on oncology. The extension follows Helix’s acquisition of Laevoroc Immunology’s assets and is underpinned by encouraging metaShape-led preclinical data on MS 001 (LEUMUNA), which has shown improved weight-loss durability and metabolic efficiency in obese mice when used alongside GLP-1 therapies, potentially positioning both companies to benefit from growing demand for next-generation obesity and cardiometabolic treatments if the program advances successfully into clinical development.
The most recent analyst rating on (TSE:HBP) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Helix BioPharma stock, see the TSE:HBP Stock Forecast page.
Spark’s Take on TSE:HBP Stock
According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Neutral.
The score is held down primarily by weak fundamentals—no revenue, ongoing losses, and continued cash burn—partly offset by a stronger balance-sheet position (low leverage) and improving loss/cash-flow trends. Technicals are supportive with the stock above key moving averages, while valuation is difficult to support due to losses and no dividend yield.
To see Spark’s full report on TSE:HBP stock, click here.
More about Helix BioPharma
Helix BioPharma is a clinical-stage oncology company focused on developing novel therapies for hard-to-treat cancers. Its pipeline is led by Tumor Defense Breaker L-DOS47, an antibody-enzyme conjugate targeting CEACAM6-expressing tumors to improve responsiveness to existing cancer treatments, alongside next-generation bispecific ADCs in discovery. The company is also advancing two pre-IND oral candidates: LEUMUNA, an immune checkpoint modulator targeting post-transplant leukemia relapse, and GEMCEDA, a gemcitabine prodrug designed to offer IV-comparable bioavailability for advanced cancers.
Average Trading Volume: 2,116
Technical Sentiment Signal: Buy
Current Market Cap: C$137.5M
For a thorough assessment of HBP stock, go to TipRanks’ Stock Analysis page.